Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Autoimmune Premature Ovarian Insufficiency
NCT05586737Phase 2Completed
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in premature ovarian insufficiency (POI). Started Apr 2019; status: completed.
02
Drugs
rituximab
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05586737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586737.